Literature DB >> 34172912

Orofacial adverse effects of COVID-19 vaccines exist but are rare.

Ahmad Sofi-Mahmudi1.   

Abstract

Data sources The US Food and Drug Administration (FDA), Health Canada, European Medicines Agency (EMA)/European Commission and UK's Medicines and Healthcare products Regulatory Agency (MHRA).Study selection Product monographs, product information and consumer medicine information for the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines.Data extraction and synthesis Reported side/adverse/undesirable effects concerning the orofacial region were extracted and tabulated.Results There were rare reports of adverse events affecting the orofacial region for both vaccines in their pertaining documents, including acute peripheral facial paralysis (Bell's palsy), facial swelling and swelling of the lips, face or tongue associated with anaphylaxis. There was heterogeneity in the acknowledgement of vaccine-related adverse events in North America compared with Europe.Conclusions There are rare reports of orofacial adverse effects of two mRNA-based COVID-19 vaccines in their documents; however, there are inconsistencies in the description of these adverse effects in different countries.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34172912      PMCID: PMC8226342          DOI: 10.1038/s41432-021-0178-y

Source DB:  PubMed          Journal:  Evid Based Dent        ISSN: 1462-0049


  9 in total

1.  AstraZeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2021-04-08

2.  Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP).

Authors:  Robb Butler; Noni E MacDonald
Journal:  Vaccine       Date:  2015-04-18       Impact factor: 3.641

3.  Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.

Authors:  Nina H Schultz; Ingvild H Sørvoll; Annika E Michelsen; Ludvig A Munthe; Fridtjof Lund-Johansen; Maria T Ahlen; Markus Wiedmann; Anne-Hege Aamodt; Thor H Skattør; Geir E Tjønnfjord; Pål A Holme
Journal:  N Engl J Med       Date:  2021-04-09       Impact factor: 91.245

4.  Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.

Authors:  Marie Scully; Deepak Singh; Robert Lown; Anthony Poles; Tom Solomon; Marcel Levi; David Goldblatt; Pavel Kotoucek; William Thomas; William Lester
Journal:  N Engl J Med       Date:  2021-04-16       Impact factor: 91.245

5.  Vaccine confidence in the time of COVID-19.

Authors:  Emily A Harrison; Julia W Wu
Journal:  Eur J Epidemiol       Date:  2020-04-22       Impact factor: 8.082

6.  Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns.

Authors:  Nicola Cirillo
Journal:  J Oral Pathol Med       Date:  2021-02-19       Impact factor: 3.539

7.  Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.

Authors:  Kate-Lynn Muir; Avyakta Kallam; Scott A Koepsell; Krishna Gundabolu
Journal:  N Engl J Med       Date:  2021-04-14       Impact factor: 91.245

8.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.

Authors:  Andreas Greinacher; Thomas Thiele; Theodore E Warkentin; Karin Weisser; Paul A Kyrle; Sabine Eichinger
Journal:  N Engl J Med       Date:  2021-04-09       Impact factor: 91.245

9.  Vaccine hesitancy: the next challenge in the fight against COVID-19.

Authors:  Amiel A Dror; Netanel Eisenbach; Shahar Taiber; Nicole G Morozov; Matti Mizrachi; Asaf Zigron; Samer Srouji; Eyal Sela
Journal:  Eur J Epidemiol       Date:  2020-08-12       Impact factor: 8.082

  9 in total
  2 in total

Review 1.  COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review.

Authors:  Faizan Zarreen Simnani; Dibyangshee Singh; Ramneet Kaur
Journal:  3 Biotech       Date:  2021-12-12       Impact factor: 2.406

Review 2.  Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations.

Authors:  Sally A Helmy; Rasha M El-Morsi; Soha A M Helmy; Soha M El-Masry
Journal:  J Drug Deliv Sci Technol       Date:  2022-09-08       Impact factor: 5.062

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.